LeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report report published on Thursday.

Several other research analysts also recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 target price for the company. JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Barrington Research boosted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Price Performance

LMAT stock opened at $107.97 on Thursday. The company has a market capitalization of $2.43 billion, a P/E ratio of 59.00, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89. The firm’s fifty day simple moving average is $93.85 and its 200-day simple moving average is $86.91. LeMaitre Vascular has a 12 month low of $51.70 and a 12 month high of $108.09.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same period in the prior year, the firm posted $0.33 earnings per share. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, sell-side analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co raised its position in shares of LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after buying an additional 6,875 shares during the period. Quadrature Capital Ltd lifted its stake in shares of LeMaitre Vascular by 129.4% in the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock valued at $1,484,000 after purchasing an additional 12,654 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $1,010,000. Finally, Harbor Capital Advisors Inc. lifted its position in LeMaitre Vascular by 240.2% in the second quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock valued at $929,000 after buying an additional 7,976 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.